Clopidogrel-drug interactions.

@article{Bates2011ClopidogreldrugI,
  title={Clopidogrel-drug interactions.},
  author={Eric R. Bates and Wei C. Lau and Dominick Joseph Angiolillo},
  journal={Journal of the American College of Cardiology},
  year={2011},
  volume={57 11},
  pages={
          1251-63
        }
}

Figures from this paper

Clopidogrel Interactions: Consider while prescribing
TLDR
The clopidogrel is commonly prescribed in many serious disorders such as cardiovascular, hypercholesteraemia and lack of information or uncertainty may cost serious outcomes.
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
Clopidogrel drug interactions: a review of the evidence and clinical implications
TLDR
Most studies assessing the clinical implications of clopidogrel–drug interactions have not shown to significantly affect outcomes, however, awareness of these DDIs remains important for optimizing the selection of concomitant therapies.
Pharmacology and Factors Affecting the Therapeutic Efficacy of Clopidogrel
TLDR
The purpose of this review is to discuss the contribution of individual factors responsible for variations of action and clopidogrel efficacy, which will be very useful for physicians, pharmacists, and healthcare personnel for considering and increasing the safety and efficacy of clopIDogrel therapy.
Genetics of platelet inhibitor treatment.
TLDR
Loss-of-function polymorphisms in CYP2C19 are the strongest individual variables affecting pharmacokinetics and antiplatelet response to clopidogrel, but explain no more than 5 to 12% of the variability in adenosine diphosphate-induced platelet aggregation on clopIDogrel.
Amlodipine – not a significant contributor to clopidogrel non-response?
TLDR
The finding that carriers of CYP2C19*2 polymorphisms who are treated with clopidogrel after coronary stenting are at increased risk of adverse thrombotic events is examined, as well as the importance of individual CYP450 enzymes in clopIDogrel metabolism to its active form.
High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.
TLDR
This review will focus on the current status of alternate strategies for more sufficient suppression of high platelet reactivity and the use of other anti-platelet medications or alternative dosing strategies for clopidogrel in patients with reduced effectiveness of clopIDogrel.
Cytochrome P450-mediated cardiovascular drug interactions
  • A. Scheen
  • Biology, Medicine
    Expert opinion on drug metabolism & toxicology
  • 2011
TLDR
Clinicians are encouraged to develop their knowledge of CYP-mediated DDIs so that they can choose safe drug combination regimens, adjust drug dosages appropriately and conduct therapeutic drug monitoring for drugs with narrow therapeutic indices.
Beneficial Pharmacokinetic Drug Interactions
TLDR
An overview of the theoretical rationale for beneficial drug interactions with specific examples of interactions that are currently being used clinically or actively undergoing research is provided.
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
TLDR
This review aimed to review the literature on factors associated with the variable platelets reactivity response to clopidogrel, as well as appraising current methods for the personalization of clopIDogrel therapy.
...
...

References

SHOWING 1-10 OF 109 REFERENCES
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
TLDR
Patients receiving dual antiplatelet treatment with aspirin and clopidogrel are commonly treated with proton pump inhibitors (PPIs), and the impact of different PPIs (pantoprazole, omeprazoles, esomeprazole) on platelet response to clopinogrel in patients with previous coronary stent placement under chronic clopIDogrel treatment is investigated.
Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition
TLDR
CCBs decrease clopidogrel-mediated platelet inhibition in patients undergoing angioplasty and stenting for cardiovascular disease.
Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance
TLDR
Measurement of antiplatelet drug efficacy with a point-of-care device and alternative antithrombotic strategies for aspirin or clopidogrel nonresponders and low responders could reduce the incidence of thromBotic events that continue to occur despite oral antiplatelets therapy.
Calcium channel blockers reduce the antiplatelet effect of clopidogrel
TLDR
Coadministration of CCBs is associated with decreased platelet inhibition by clopidogrel, indicating that the negative effect occurs in vivo, conceivably at the level of the CYP3A4 cytochrome.
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
TLDR
The antiplatelet effect of clopidogrel is not attenuated by concomitant treatment with a CYP3A4 metabolized statin in patients with clinical stable ischemic heart disease and statin treatment given concomitantly with clopIDogrel resulted in an improved platelet inhibition when compared to clopinogrel given alone.
Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction
TLDR
CYP3A4 activates clopidogrel and atorvastatin competitively inhibits this activation and use of a statin not metabolized by Cytochrome P450 (CYP) 3A4 and point-of-care platelet function testing may be warranted in patients treated with clopIDogrel.
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel
TLDR
The response to clopidogrel before and during administration of rifampicin was studied in order to study the relationship between individual AM levels and P2Y12 blockade and greater inhibition of PA.
...
...